Microbot Medical Debuts at Oppenheimer Conference Amid LIBERTY System Rollout
Event summary
- Microbot Medical to present at Oppenheimer Healthcare MedTech Conference March 19, 2026.
- CEO Harel Gadot to highlight LIBERTY system's limited market release progress.
- CFO Rachel Vaknin and VP Earl Adamy available for investor meetings March 18, 2026.
- Company plans full market release of LIBERTY system at SIR conference in April 2026.
- LIBERTY is the only FDA-cleared single-use robotic system for peripheral endovascular procedures.
The big picture
Microbot Medical's conference debut signals growing institutional interest in its differentiated robotic endovascular technology. The company is positioning itself as a disruptor in the $12B+ peripheral vascular intervention market, competing with established players like Medtronic and Boston Scientific. Success will depend on demonstrating superior clinical outcomes and cost efficiency as it scales commercial operations.
What we're watching
- Market Adoption
- How the limited market release performance will translate to full commercialization success.
- Competitive Positioning
- Whether Microbot can establish LIBERTY as a category leader in endovascular robotics.
- Regulatory Pathway
- The pace at which additional FDA clearances or international approvals might be secured.